Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q2 2025 value amounting to $14000.0.

  • Bolt Biotherapeutics' Cash from Financing Activities fell 8227.85% to $14000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $43000.0, marking a year-over-year decrease of 7675.68%. This contributed to the annual value of $108000.0 for FY2024, which is 5731.23% down from last year.
  • Latest data reveals that Bolt Biotherapeutics reported Cash from Financing Activities of $14000.0 as of Q2 2025, which was down 8227.85% from $29000.0 recorded in Q4 2024.
  • Bolt Biotherapeutics' Cash from Financing Activities' 5-year high stood at $297.0 million during Q1 2021, with a 5-year trough of $14000.0 in Q2 2025.
  • For the 5-year period, Bolt Biotherapeutics' Cash from Financing Activities averaged around $28.3 million, with its median value being $144000.0 (2022).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 87348529.41% in 2021, then crashed by 9996.4% in 2022.
  • Quarter analysis of 5 years shows Bolt Biotherapeutics' Cash from Financing Activities stood at $495000.0 in 2021, then crashed by 70.91% to $144000.0 in 2022, then decreased by 26.39% to $106000.0 in 2023, then plummeted by 72.64% to $29000.0 in 2024, then crashed by 51.72% to $14000.0 in 2025.
  • Its Cash from Financing Activities stands at $14000.0 for Q2 2025, versus $29000.0 for Q4 2024 and $79000.0 for Q2 2024.